From concept to the clinic: Retinoic acid receptor α antagonist YCT-529, an oral non-hormonal male contraceptive

Noha Taher; Ehfazul Haque; Gunda I. Georg

doi:10.1111/andr.70106

From concept to the clinic: Retinoic acid receptor α antagonist YCT-529, an oral non-hormonal male contraceptive

Noha Taher
, Ehfazul Haque
, Gunda I. Georg

Medicinal Chemistry

Research output: Contribution to journal › Review article › peer-review

Abstract

YCT-529 reversibly reduces sperm counts to infertility levels in mice and non-human primates. Mice mating studies demonstrated 99% effectiveness in preventing pregnancies. YCT-529 has completed a first-in-class, double-blind, placebo-controlled Phase I clinical safety study in men and is currently being investigated in a Phase Ib/IIa clinical study.

Original language	English (US)
Journal	Andrology
DOIs	https://doi.org/10.1111/andr.70106
State	Accepted/In press - 2025

Bibliographical note

Publisher Copyright:
© 2025 American Society of Andrology and European Academy of Andrology.

Keywords

antagonism
contraception
male
non-hormonal
retinoic acid receptor α

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1111/andr.70106

Cite this

@article{e5a5d57d39e9498ebb03029416aa5b36,

title = "From concept to the clinic: Retinoic acid receptor α antagonist YCT-529, an oral non-hormonal male contraceptive",

abstract = "YCT-529 reversibly reduces sperm counts to infertility levels in mice and non-human primates. Mice mating studies demonstrated 99\% effectiveness in preventing pregnancies. YCT-529 has completed a first-in-class, double-blind, placebo-controlled Phase I clinical safety study in men and is currently being investigated in a Phase Ib/IIa clinical study.",

keywords = "antagonism, contraception, male, non-hormonal, retinoic acid receptor α",

author = "Noha Taher and Ehfazul Haque and Georg, \{Gunda I.\}",

note = "Publisher Copyright: {\textcopyright} 2025 American Society of Andrology and European Academy of Andrology.",

year = "2025",

doi = "10.1111/andr.70106",

language = "English (US)",

journal = "Andrology",

issn = "2047-2919",

publisher = "John Wiley \& Sons Inc.",

}

TY - JOUR

T1 - From concept to the clinic

T2 - Retinoic acid receptor α antagonist YCT-529, an oral non-hormonal male contraceptive

AU - Taher, Noha

AU - Haque, Ehfazul

AU - Georg, Gunda I.

PY - 2025

Y1 - 2025

N2 - YCT-529 reversibly reduces sperm counts to infertility levels in mice and non-human primates. Mice mating studies demonstrated 99% effectiveness in preventing pregnancies. YCT-529 has completed a first-in-class, double-blind, placebo-controlled Phase I clinical safety study in men and is currently being investigated in a Phase Ib/IIa clinical study.

AB - YCT-529 reversibly reduces sperm counts to infertility levels in mice and non-human primates. Mice mating studies demonstrated 99% effectiveness in preventing pregnancies. YCT-529 has completed a first-in-class, double-blind, placebo-controlled Phase I clinical safety study in men and is currently being investigated in a Phase Ib/IIa clinical study.

KW - antagonism

KW - contraception

KW - male

KW - non-hormonal

KW - retinoic acid receptor α

UR - https://www.scopus.com/pages/publications/105013024987

UR - https://www.scopus.com/pages/publications/105013024987#tab=citedBy

U2 - 10.1111/andr.70106

DO - 10.1111/andr.70106

M3 - Review article

C2 - 40797283

AN - SCOPUS:105013024987

SN - 2047-2919

JO - Andrology

JF - Andrology

ER -

From concept to the clinic: Retinoic acid receptor α antagonist YCT-529, an oral non-hormonal male contraceptive

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Other files and links

Fingerprint

Cite this